Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results - Earnings Call ... Seeking Alpha We continue to make progress with our mid-stage pipeline and expect 3 pivotal readouts over the next 3 years: daclizumab in 2014, TYSABRI and SPMS in 2015 and potentially, SMNRx in 2016. During that time frame, we also expect to have meaningful data ... The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As ... |
